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C9orf72 repeat expansions are a common cause of amyotrophic lateral sclerosis and frontotemporal
dementia. To date, no large-scale study of dementia with Lewy bodies (DLB) has been undertaken to
assess the role of C9orf72 repeat expansions in the disease. Here, we investigated the prevalence of
C9orf72 repeat expansions in a large cohort of DLB cases and identiﬁed no pathogenic repeat expansions
in neuropathologically or clinically deﬁned cases, showing that C9orf72 repeat expansions are not
causally associated with DLB.
 2016 Elsevier Inc. All rights reserved.1. Introduction
Hexanucleotide repeat expansions (HREs) in a noncoding region
of C9orf72 are recognized as the most common genetic cause of
familial and sporadic amyotrophic lateral sclerosis, frontotemporal
dementia (FTD), amyotrophic lateral sclerosis-FTD, and Huntington
disease phenocopies (Beck et al., 2013; Boeve et al., 2012; Hensman
Moss et al., 2014; Majounie et al., 2012c; Simon-Sanchez et al.,
2012; van der Zee et al., 2013).
A normal repeat expansion shows 1 to 23 GGGGCC repeats
located between exons 1a and 1b of C9orf72 (DeJesus-Hernandez
et al., 2011; Renton et al., 2011). HREs identiﬁed in several neuro-
degenerative syndromes were found to range from 500 to 4400
repeats, but on a repeat-primed polymerase chain reaction (PCR),
more than 32 repeats are often considered a pathogenic genotype
(Beck et al., 2013).
C9orf72 HREs have been identiﬁed in nonmotor neurodegener-
ative phenotypes including Alzheimer’s disease (AD) at frequencies
of w1% (Beck et al., 2013; Harms et al., 2013; Kohli et al., 2013;
Majounie et al., 2012b), although conﬂicting reports exist in the
literature (Rollinson et al., 2012; Xi et al., 2012).
Dementia with Lewy bodies (DLB) accounts for 15%e25% of all
dementia cases (Heidebrink, 2002). Its core features encompass
cognitive impairment, ﬂuctuating attention, parkinsonism, and
recurrent visual hallucinations (Weisman and McKeith, 2007).
Neuropathological diagnosis of DLB is achieved when the presence
of Lewy bodies is conﬁrmed in the cortex and the brainstem
(McKeith et al., 2005). Little is known about the genetics of DLB,
although molecular studies seem to point toward genetic overlaps
with other neurodegenerative diseases, mainly with AD and Par-
kinson’s disease (PD) (Bras et al., 2014; Guerreiro et al., 2016; Keogh
et al., 2016; Meeus et al., 2012).
So far, the C9orf72 repeat expansion has only been genotyped in
small cohorts ofw100 DLB cases or less (Geiger et al., 2016; Lesage
et al., 2013; Robinson et al., 2014; Snowden et al., 2012; Yeh et al.,
2013). We have recently shown in a large cohort that C9orf72
repeat expansions are not a common cause of DLB in pathologicallydiagnosed cases (Guerreiro et al., 2015). Here, we expand on these
ﬁndings using a cohort of 1524 DLB cases.
2. Material and methods
Samples consisted of an international cohort of 1398 neuro-
pathologically diagnosed DLB cases and 126 clinically diagnosed
DLB cases (Supplementary Table 1). DNA was extracted from brain
tissue for the neuropathologically diagnosed samples and from
blood for the clinical diagnosed samples using standard procedures.
We performed repeat-primed PCR according to Renton et al. (2011).
Genotypes were assessed using Peak Scanner v2.0 (Applied Bio-
systems) with repeat expansions displaying a characteristic saw
tooth pattern with a 6 base pair periodicity on analysis.
3. Results
Repeat mean number was 5.17 (4.30 standard deviation)
ranging from 1 to 58. All except 5 samples presented less than 23
repeats in the repeat-primed PCR (Supplementary Fig. 1). Two
neuropathologically diagnosed DLB samples showed 32 repeats and
1 showed 33 repeats; and 2 clinically diagnosed samples exhibited
33 and 58 repeats. These last 2 samples had been previously
analyzed as part of the cohort published by Snowden et al. (2012).
4. Discussion
This is the ﬁrst study genotyping the C9orf72 HREs in a large
cohort of mainly neuropathologically diagnosed DLB samples.
Within the neuropathologically deﬁned DLB cases, we did not ﬁnd
any HREs above the typical threshold for pathogenicity (w32 re-
peats). This is concordant with previous studies that found no
repeat expansions in 34 clinically diagnosed cases of a Taiwanese
cohort or in 111 pathological DLB cases (Geiger et al., 2016; Yeh
et al., 2013). Snowden et al. (2012) found 2 cases with HREs
greater than 30 repeats in a study that was comprised of 102
“probable DLB” blood samples. When the same group restricted
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pathogenic repeat expansions were identiﬁed (Robinson et al.,
2014).
DLB is considered to be part of a spectrum between AD and PD
(Weisman and McKeith, 2007) where large C9orf72 HREs are not
frequent. In AD, it was suggested that pathogenic repeat expansions
may only be associated with late onset AD (Kohli et al., 2013) or that
amnesic FTD (which is easily misdiagnosed as AD) could be
responsible for the low frequencies observed for AD (Majounie
et al., 2012b). In PD, there is no evidence for a role of C9orf72
pathogenic repeat expansions (Majounie et al., 2012a; Xi et al.,
2012).
Clinical symptoms in DLB can vary substantially from patient to
patient and some can even overlap with less typical forms of FTD
(Claassen et al., 2008), which could account for the pathogenic
repeat expansions found in misdiagnosed DLB clinical cases.
Furthermore, recent data suggest that the threshold for pathoge-
nicity of HREs should be higher than the initially proposed 30 re-
peats (Xi et al., 2015).
In our cohort of neuropathologically diagnosed DLB samples, we
found 3 cases with likely benign 32 and 33 repeats. Excluding the
clinically diagnosed cases, we found no evidence of pathogenic
repeat expansions. Even including the clinically diagnosed cohort,
no extended repeat expansions were identiﬁed; with the longest
allele exhibiting 58 repeats.
Our study shows that C9orf72 pathogenic repeat expansions are
not a common cause of DLB.
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